Korean J Dermatol.  2015 May;53(4):324-327.

Acneiform Eruption Induced by Dacomitinib (PF-00299804)

• Park SY
• Suh DH

Abstract

Dacomitinib (PF-00299804) is a newly developed irreversible pan-HER (human epidermal growth factor receptor) inhibitor for the treatment of non-small cell lung cancer (NSCLC). Inhibiting HER-1 (epidermal growth factor receptor, EGFR), HER-2, and HER-4 may induce similar cutaneous side effects to those of traditional EGFR inhibitors. We report two patients who developed acneiform eruption on the face and trunk, induced by dacomitinib treatment for NSCLC. The skin lesions appeared 3~4 weeks after the initiation of dacomitinib use, and they improved after oral minocycline and topical clindamycin treatment. There has been no report of acneiform eruption after dacomitinib treatment in Korean dermatology journals.

Keyword

Acneiform eruption; Chemotherapy; Dacomitinib; Epidermal growth factor receptor inhibitor

MeSH Terms

Acneiform Eruptions*
Carcinoma, Non-Small-Cell Lung
Clindamycin
Dermatology
Drug Therapy
Epidermal Growth Factor
Humans
Minocycline
Skin
Clindamycin
Epidermal Growth Factor
Minocycline